It is possible that further delineation of the role of MYH9 and APOL1 variants may lead, in the future, to improved screening programs, prevention strategies and clinical interventions for CKD, one of the most common end-organ causes of morbidity and mortality worldwide. This evidence concerns the gene MYH9 and chronic kidney disease.